Celltrion Reports Submission of MAA to EMA for CT-P17 (biosimilar, adalimumab)

Celltrion Reports Submission of MAA to EMA for CT-P17 (biosimilar, adalimumab)

Shots:

  • Celltrion has applied for the commercial approval of CT-P17, a biosimilar referencing Humira (adalimumab) in the EU
  • The submission is based on clinical data targeting all approved indications of Humira, including RA, UC, and psoriasis and is expected to be available in the EU market in about a year. Additionally, Celltrion is conducting P-III clinical studies of CT-P16 (biosimilar, bevacizumab) referencing Genentech’s Avastin for multiple cancer indications
  • CT-P17 is the first high-concentration adalimumab biosimilar and is different from the existing biosimilars of Humira in terms of dosing. The drug is citrate free that means it will cause less pain upon injection

Click here ­to­ read full press release/ article | Ref: Korean Herald | Image: Celltrion